USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
Humans
Male
Cell Line, Tumor
Cell Proliferation
/ genetics
Disease Progression
Gene Expression Regulation, Neoplastic
Histones
/ metabolism
Promoter Regions, Genetic
/ genetics
Prostatic Neoplasms
/ genetics
Prostatic Neoplasms, Castration-Resistant
/ genetics
Proto-Oncogene Proteins c-myc
/ metabolism
Receptors, Androgen
/ metabolism
Thiolester Hydrolases
/ metabolism
Ubiquitination
Up-Regulation
AR
c-Myc
gene expression
prostate cancer
ubiquitination
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
ppublish
Résumé
Androgen receptor (AR) is a main driver for castration-resistant prostate cancer (CRPC). c-Myc is an oncogene underlying prostate tumorigenesis. Here, we find that the deubiquitinase USP11 targets both AR and c-Myc in prostate cancer (PCa). USP11 expression was up-regulated in metastatic PCa and CRPC. USP11 knockdown (KD) significantly inhibited PCa cell growth. Our RNA-seq studies revealed AR and c-Myc as the top transcription factors altered after USP11 KD. ChIP-seq analysis showed that either USP11 KD or replacement of endogenous USP11 with a catalytic-inactive USP11 mutant significantly decreased chromatin binding by AR and c-Myc. We find that USP11 employs two mechanisms to up-regulate AR and c-Myc levels: namely, deubiquitination of AR and c-Myc proteins to increase their stability and deubiquitination of H2A-K119Ub, a repressive histone mark, on promoters of AR and c-Myc genes to increase their transcription. AR and c-Myc reexpression in USP11-KD PCa cells partly rescued cell growth defects. Thus, our studies reveal a tumor-promoting role for USP11 in aggressive PCa through upregulation of AR and c-Myc activities and support USP11 as a potential target against PCa.
Identifiants
pubmed: 39052835
doi: 10.1073/pnas.2403331121
doi:
Substances chimiques
AR protein, human
0
Histones
0
MYC protein, human
0
Proto-Oncogene Proteins c-myc
0
Receptors, Androgen
0
Thiolester Hydrolases
EC 3.1.2.-
USP11 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2403331121Subventions
Organisme : HHS | NIH | National Cancer Institute (NCI)
ID : R01CA244667
Organisme : U.S. Department of Defense (DOD)
ID : PC210437
Déclaration de conflit d'intérêts
Competing interests statement:The authors declare no competing interest.